A Proud Milestone for Orbital Therapeutics and RNA Medicines

A remarkable milestone for Orbital Therapeutics and for the broader field of RNA medicines. It is also an especially proud one at home.

Carol helped co-found Orbital around a bold scientific vision that circular RNA could unlock a new class of durable medicines. Seeing that vision validated through Bristol Myers Squibb’s $1.5 billion acquisition is a testament to her conviction and to the exceptional team that made it real.

Congratulations to Carol Suh, Howard Chang, Giuseppe Ciaramella, John Evans, Ron Philip, and Kristina Burow and John Maraganore on the ARCH Venture Partners team. This is how new therapeutic paradigms are built.

To new orbits 🚀